Wednesday, September 18, 2024
Drug-resistant infections are on the rise – so why aren’t we getting any new antibiotics?
Some of those programmes exist already. In the UK, drug companies can receive a fixed annual fee for new antibiotics regardless of how much they are used. The subscription model bases payments on how valuable the drugs are to the health system.
Subscribe to:
Post Comments (Atom)
Click Older Posts above to see more.
No comments:
Post a Comment